Pfizer Medical Information

Contact Pfizer about TORISEL

Customer Service:

1-800-395-9938

Register Now

To get contact information for your regional sales representative.

Health Care Professionals Log In

Sign up for TORISEL Updates

Gain access to additional
content on the TORISEL Web
site and receive updates.
You'll also get free, unlimited
access to:

  • The 5 minute Clinical Consult
    2009
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets
Torisel Banner

Relative Dose Intensity

TORISEL patients on average received 92% of the planned weekly dose1

TORISEL patients on average received 92% of the weekly dose

  • TORISEL mean weekly dose was 23 mg, and the max planned weekly dose was 25 mg1
  • IFN-α mean weekly dose was 30 MU, and the max planned weekly dose was 54 MU1

Reasons For Discontinuation

Patient discontinuation due to adverse events was 7.2% with TORISEL2

Reason for Discontinuation TORISEL
(n=208)		 IFN-α
(n=200)
Adverse event 7.2% 14.5%
Symptomatic deterioration* 6.7% 14.0%
Patient request 3.8% 3.0%
Death 2.9% 5.0%
Other 1.0%† 2.0%‡
Protocol violation 0.5% 1.0%
Disease progression 73.6% 57.5%

* Subjects with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration.”2

† Other reasons for discontinuation in the TORISEL arm were disease progression and investigator’s decision.2

‡ Other reasons for discontinuation in the IFN-α arm were lost to follow up, investigator’s discretion, patient underwent surgery, and patient’s request.2

Next: Clinical Trial Design and Results »

TORISEL Interactive Review

Participate in an interactive review of the published TORISEL phase 3 clinical trial.

Important Safety Information

Important Safety Information

  • TORISEL is contraindicated in patients with bilirubin >1.5 x ULN and should be used with caution when treating patients with mild hepatic impairment (bilirubin >1 – 1.5 x ULN or AST > ULN but bilirubin ≤ ULN). If TORISEL must be given to patients with mild hepatic impairment, reduce the dose of TORISEL to 15 mg/week. In a phase 1 study, the overall frequency of ≥ grade 3 adverse reactions and deaths, including deaths due to progressive disease, was greater in patients with baseline bilirubin > 1.5 x ULN.
  • Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing, and chest pain have been observed with TORISEL.
  • Serum glucose, serum cholesterol, and triglycerides should be tested before and during treatment with TORISEL.
    • The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy and/or lipid-lowering agents, respectively.
  • The use of TORISEL may result in immunosuppression. Patients should be carefully observed for the occurrence of infections, including opportunistic infections.
  • Cases of interstitial lung disease, some resulting in death, have occurred. Some patients were asymptomatic and others presented with symptoms. Some patients required discontinuation of TORISEL and/or treatment with corticosteroids and/or antibiotics.
  • Cases of fatal bowel perforation occurred with TORISEL. These patients presented with fever, abdominal pain, metabolic acidosis, bloody stools, diarrhea, and/or acute abdomen.
  • Cases of rapidly progressive and sometimes fatal acute renal failure not clearly related to disease progression occurred in patients who received TORISEL.
  • Due to abnormal wound healing, use TORISEL with caution in the perioperative period.
  • Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes) while receiving TORISEL.
  • Live vaccinations and close contact with those who received live vaccines should be avoided.
  • Patients and their partners should be advised to avoid pregnancy throughout treatment and for 3 months after TORISEL therapy has stopped.
  • The most common (incidence ≥30%) adverse reactions observed with TORISEL are: rash (47%), asthenia (51%), mucositis (41%), nausea (37%), edema (35%), and anorexia (32%). The most common laboratory abnormalities (incidence ≥30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%).
  • Most common grades 3/4 adverse events and laboratory abnormalities included asthenia (11%), dyspnea (9%), hemoglobin decreased (20%), lymphocytes decreased (16%), glucose increased (16%), phosphorus decreased (18%), and triglycerides increased (44%).
  • Strong inducers of CYP3A4/5 (eg, dexamethasone, rifampin) and strong inhibitors of CYP3A4 (eg, ketoconazole, atazanavir) may decrease and increase concentrations of the major metabolite of TORISEL, respectively. If alternatives cannot be used, dose modifications of TORISEL are recommended.
  • St. John’s Wort may decrease TORISEL plasma concentrations, and grapefruit juice may increase plasma concentrations of the major metabolite of TORISEL, and therefore both should be avoided.
  • The combination of TORISEL and sunitinib resulted in dose-limiting toxicity (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization).

Please see the full Prescribing Information for TORISEL.

References:

  1. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    N Engl J Med. 2007;356:2271-2281.
  2. Data on file, Pfizer Inc.

TRS00099